Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus EXTRANEAL.
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs EXTRANEAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-2 with Dextrose 3.5% is a peritoneal dialysis solution. Dextrose provides an osmotic gradient that facilitates the removal of uremic toxins and excess fluid from the blood across the peritoneal membrane into the dialysate. The solution also contains electrolytes to correct imbalances.
Extraneal (icodextrin) is a glucose polymer that acts as an osmotic agent for peritoneal dialysis. It is absorbed from the peritoneal cavity into the bloodstream and metabolized to maltose and other oligosaccharides. Its primary mechanism is to create an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of waste products.
2 to 3 liters intraperitoneally, 4 exchanges daily, with dwell times of 4-6 hours for CAPD; or 2 to 2.5 liters intraperitoneally, cycler-assisted, 3-5 cycles nightly for APD. Dextrose 3.5% solution used based on ultrafiltration needs.
7.5% solution: 2 L intraperitoneally, dwell time 4–8 hours, up to 4 exchanges per day. For automated peritoneal dialysis: 2 L per cycle, typically 3–5 cycles overnight.
None Documented
None Documented
The elimination half-life of dextrose from the systemic circulation is approximately 3.5-4.5 hours after intraperitoneal administration. Clinically, this reflects the rate of glucose absorption and metabolism, which can be altered in patients with impaired glucose tolerance or diabetes.
The terminal elimination half-life of icodextrin in plasma is approximately 19 hours (range 12-22 hours) following intraperitoneal administration for a dwell of 8-12 hours. This long half-life reflects slow metabolism and clearance, particularly relevant in patients with impaired renal function, leading to accumulation of maltose and other oligosaccharides.
Peritoneal dialysis (PD) with 3.5% dextrose solution results in elimination of excess fluid and solutes via the peritoneal membrane. Dextrose is absorbed systemically and metabolized. The primary route of elimination of dialytic waste products (e.g., urea, creatinine) is via the peritoneal fluid itself, which is drained. Less than 1% of dextrose is excreted unchanged in urine. Biliary/fecal excretion is negligible.
Icodextrin is metabolized to maltose, maltotriose, and other oligosaccharides. After intraperitoneal administration, approximately 40% of the administered dose is absorbed systemically; the absorbed icodextrin and its metabolites are primarily eliminated by renal excretion (via glomerular filtration). In patients with residual renal function, approximately 30-40% of the absorbed dose is excreted in urine over 14 days. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution